ACCUSTEM SCIENCES, INC.

ACUT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Operating Activities
Net Income $-1.8M $-1.5M $-2.1M $-3.7M $-670.6K
Depreciation & Amortization
Depreciation $418 $3.6K $3.6K $3.3K
Amortization
Stock-Based Compensation $88.7K $69.7K $78.6K $133.9K $21.3K
Net Cash from Operating Activities $-850.4K $-664.1K $-1.6M $-1.8M
Investing Activities
Capital Expenditures $11.0K
Business Acquisitions
Net Cash from Investing Activities $-11.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $859.3K $647.6K $903.1K $2.6M
Net Change in Cash $8.9K $-16.4K $-712.5K $734.0K
Free Cash Flow $-1.8M